Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), a much milder form of the disease where the age of onset can sometimes be as late as the third or fourth decade of life, are caused by mutations in the same X-linked gene, a 14 kilobase (kb) transcript which is spread over more than 2 megabases of the human X chromosome. The corresponding protein, dystrophin, has a relative molecular mass of 400,000. Most mutations causing DMD and BMD are deletions and deletions associated with both phenotypes are observed throughout the gene sequence. This observation led to the suggestion that DMD patients possess deletions that disrupt the reading frame of the protein, whereas BMD patients have deletions that retain the translational reading frame and enable the muscle cells to produce altered dystrophin products. This theory is supported by immunoblotting studies, which show that DMD patients lack dystrophin in their muscle cells or that dystrophin is present at very low levels, whereas BMD patients produce a protein with reduced abundance or abnormal size. Here we describe a deletion of the dystrophin gene in a family segregating for very mild BMD, one member of which was still ambulant at age 61 years, which removes a central part of the dystrophin gene encompassing 5,106 base pairs of coding sequence, almost half the coding information. Immunological analysis of muscle from one of the patients demonstrates that this mutation results in the production of a truncated polypeptide localized correctly in the muscle cell. These results are particularly significant in the context of gene therapy which, if it is ever envisaged, would be facilitated by the replacement of the very large dystrophin gene with a more manipulatable mini-gene construct.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, many shortened versions of the Duchenne muscular dystrophy gene (DMD; 2.3 Mb; 79-exons; 3685 amino acids; 11,055 bp) do not rescue the Duchenne muscular dystrophy phenotype in muscle cells except for the micro-dystrophin for which was reported a milder clinical phenotype [183,184].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [184]
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Self-citationThe Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle
Zubrzycka-Gaarn, E. E., Bulman, D. E., Karpati, G., Burghes, A. H. M., Belfall, B., Klamut, H. J., Talbot, J., Hodges, R. S., Ray, P. N., & Worton, R. G. (1988) · Nature · doi:10.1038/333466a0 · Cited by 658
Self-citationAn autosomal transcript in skeletal muscle with homology to dystrophin
Love, D. R., Hill, D. F., Dickson, G., Spurr, N. K., Byth, B. C., Marsden, R. F., Walsh, F. S., Edwards, Y. H., & Davies, K. E. (1989) · Nature · doi:10.1038/339055a0 · Cited by 494
Self-citationAnalysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy
co-authors, & Kunkel, L. M. (1986) · Nature · doi:10.1038/322073a0 · Cited by 474
Immunoelectron microscopic localization of dystrophin in myofibres
Watkins, S. C., Hoffman, E. P., Slayter, H. S., & Kunkel, L. M. (1988) · Nature · doi:10.1038/333863a0 · Cited by 449
Davies, K. E., Pearson, P. L., Harper, P. S., Murray, J. M., O'Brien, T., Sarfarazi, M., & Williamson, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.8.2303 · Cited by 397
Self-citation
Research works printed but not linked: 5
- Darras, B. T. & Francke, U. Am. J. hum. Genet. 43, 612–619 (1988).
- Love, D. R. & Davies, K. E. Molec biol. Med. 6, 7–17 (1989).
- Davies, K. E. et al. J. Med. Genet. 99, 99 (1987).
- Koenig, M., et al. Am. J. hum. Genet. 45, 498–506 (1989).
- Den Dunnen, J. T. Am. J. hum. Genet, in the press.
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Function and Genetics of Dystrophin and Dystrophin-Related Proteins in Muscle
Blake, D. J., Weir, A., Newey, S. E., & Davies, K. E. (2002) · Physiological Reviews · doi:10.1152/physrev.00028.2001 · Cited by 1,242
Self-citationIn vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Dystrophin and mutations: one gene, several proteins, multiple phenotypes
Muntoni, F., Torelli, S., & Ferlini, A. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00585-4 · Cited by 1,124
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Aartsma‐Rus, A., Van Deutekom, J. C. T., Fokkema, I. F., Van Ommen, G. B., & Den Dunnen, J. T. (2006) · Muscle & Nerve · doi:10.1002/mus.20586 · Cited by 739
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“The adoption of a truncated version of dystrophin as a possible treatment for DMD is based on a Becker muscular dystrophy patient who remained ambulatory for seven decades despite a deletion of nearly half his DMD gene.(26) Currently, transgenes incorporating diverse numbers of spectrin repeats (SRs) and hinges and de…”
MethodSystemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678
The structural and functional diversity of dystrophin
Ahn, A. H., & Kunkel, L. M. (1993) · Nature Genetics · doi:10.1038/ng0493-283 · Cited by 650
Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy
Harper, S. Q., Hauser, M. A., DelloRusso, C., Duan, D., Crawford, R. W., Phelps, S. F., Harper, H. A., Robinson, A. S., Engelhardt, J. F., Brooks, S. V., et al. (2002) · Nature Medicine · doi:10.1038/nm0302-253 · Cited by 579
“Large, in-frame deletions in the central-rod domain often lead to the milder Becker muscular dystrophy (BMD”
BackgroundCRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
“This strategy is particularly well suited for Duchene muscular dystrophy (DMD), which is caused by several different mutations, all of which can be treated with this strategy because truncated dystrophin protein with internal deletions is partially functional (England et al., 1990).”
The Dystrophin Complex: Structure, Function, and Implications for Therapy
Gao, Q. Q., & McNally, E. M. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c140048 · Cited by 456
“One dramatic example of an in-frame DMD gene mutation was described that removed 46% of the coding sequence (exons 17-48) (53).”
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy
McGreevy, J. W., Hakim, C. H., McIntosh, M. A., & Duan, D. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.018424 · Cited by 512
“The first clue about this came from a mildly affected individual, who was ambulant at age 61 (England et al., 1990).”
BackgroundWang, B., Li, J., & Xiao, X. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240335297 · Cited by 508
Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A., & Lu, Q. L. (2006) · Nature Medicine · doi:10.1038/nm1345 · Cited by 494
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Animal models for muscular dystrophy show different patterns of sarcolemmal disruption
Straub, V., Rafael, J. A., Chamberlain, J. S., & Campbell, K. P. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.2.375 · Cited by 488
“In contrast, D17-48 transgenic/mdx mice, which mimic the dystrophin mutation in an extremely mild case of Becker muscular dystrophy (England et al., 1990; Phelps et al., 1995), and D71-74 transgenic/mdx mice, which have been reported to show no dystrophic phenotype up to at least 2 yr of age…”
BackgroundHuman dystrophin expression in mdx mice after intramuscular injection of DNA constructs
Acsadi, G., Dickson, G., Love, D. R., Jani, A., Walsh, F. S., Gurusinghe, A., Wolff, J. A., & Davies, K. E. (1991) · Nature · doi:10.1038/352815a0 · Cited by 485
Self-citationEfficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice
Ragot, T., Vincent, N., Chafey, P., Vigne, E., Gilgenkrantz, H., Coutont, D., Cartaud, J., Briand, P., Kaplant, J.-C., Perricaude, M., et al. (1993) · Nature · doi:10.1038/361647a0 · Cited by 457
Allen, D. G., Whitehead, N. P., & Froehner, S. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00007.2015 · Cited by 426
“Based on the observation of a relatively mild clinical phenotype in a Becker MD patient with a deletion of exons 17–48 (115), dystrophin mini genes have been designed, which lack many of the spectrin repeats but retain much of the functionality (168) including the nNOS binding site (229).”
BackgroundBeggs, A. H., Hoffman, E. P., Snyder, J. R., Arahata, K., Specht, L. A., Shapiro, F., Angelini, C. I., Sugita, H., & Kunkel, L. M. (1991) · PubMed · Cited by 410
Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J. E., Partridge, T. A., & Wilton, S. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.42 · Cited by 388
Mendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1484 · Cited by 405
Lu, Q. L., Rabinowitz, A., Chen, Y. C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G., & Partridge, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406700102 · Cited by 402
Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs
Yokota, T., Lu, Q., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S., & Hoffman, E. (2009) · Annals of Neurology · doi:10.1002/ana.21627 · Cited by 398
“Some BMD patients with deletions as large as 33 exons (46% of the gene) can show little or no clinical symptoms, with only increased serum creatine kinase concentration.(4) This raises the possibility of using antisense-mediated removal of exons carrying nonsense mutations, or whose presence disrupts the open reading…”
BackgroundFunctional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse
Lu, Q. L., Mann, C. J., Lou, F., Bou-Gharios, G., Morris, G. E., Xue, S.-A., Fletcher, S., Partridge, T. A., & Wilton, S. D. (2003) · Nature Medicine · doi:10.1038/nm897 · Cited by 398
“If it proves possible to skip multiple exons, then a transcript corresponding to the minidystrophin deletion of exons 17–49 would represent a common optimu”
BackgroundThyroid hormones and skeletal muscle—new insights and potential implications
Salvatore, D., Simonides, W. S., Dentice, M., Zavacki, A. M., & Larsen, P. R. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.238 · Cited by 391
Primary structure of dystrophin-related protein
Tinsley, J. M., Blake, D. J., Roche, A., Fairbrother, U., Riss, J., Byth, B. C., Knight, A. E., Kendrick-Jones, J., Suthers, G. K., Love, D. R., et al. (1992) · Nature · doi:10.1038/360591a0 · Cited by 391
Self-citationLai, Y., Thomas, G. D., Yue, Y., Yang, H. T., Li, D., Long, C., Judge, L., Bostick, B., Chamberlain, J. S., Terjung, R. L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36612 · Cited by 389
Dystrophin-Deficient Cardiomyopathy
Kamdar, F., & Garry, D. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.081 · Cited by 384
“However, the observation of mildly affected patients with BMD who had very large dystrophin gene deletions led to the understanding that truncated dystrophins could be functional (85,108).”
Therapeutic developments for Duchenne muscular dystrophy
Verhaart, I. E. C., & Aartsma-Rus, A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0203-3 · Cited by 377
The Pathogenesis and Therapy of Muscular Dystrophies
Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G.-J. B., & Kunkel, L. M. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-025003 · Cited by 302
“Furthermore, very mildly affected Becker muscular dystrophy patients lack the nNOS binding site (71), suggesting that there may be compensatory nNOS pathways.”
BackgroundSelf-citationAdenovirus as an expression vector in muscle cells in vivo.
Quantin, B., Perricaudet, L. D., Tajbakhsh, S., & Mandel, J. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2581 · Cited by 296
Mechanical function of dystrophin in muscle cells.
Pasternak, C., Wong, S., & Elson, E. L. (1995) · The Journal of cell biology · doi:10.1083/jcb.128.3.355 · Cited by 292
Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications
Aartsma-Rus, A., & van Ommen, G.-J. B. (2007) · RNA · doi:10.1261/rna.653607 · Cited by 267
“Dystrophin can be largely functional as long as the N- and C-terminal domains are present to convey the link between the cytoskeleton and the extracellular matrix (England et al. 1990; Mirabella et al. 1998).”
BackgroundImmunolocalization and developmental expression of dystrophin related protein in skeletal muscle
Khurana, T. S., Watkins, S. C., Chafey, P., Chelly, J., Tomé, F. M. S., Fardeau, M., Kaplan, J.-C., & Kunkel, L. M. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90023-l · Cited by 263
Mor, A., Suliman, S., Ben-Yishay, R., Yunger, S., Brody, Y., & Shav-Tal, Y. (2010) · Nature Cell Biology · doi:10.1038/ncb2056 · Cited by 262
A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy
Mendell, J. R., Sahenk, Z., Malik, V., Gomez, A. M., Flanigan, K. M., Lowes, L. P., Alfano, L. N., Berry, K., Meadows, E., Lewis, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.200 · Cited by 246
CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice
Xu, L., Park, K. H., Zhao, L., Xu, J., El Refaey, M., Gao, Y., Zhu, H., Ma, J., & Han, R. (2016) · Molecular Therapy · doi:10.1038/mt.2015.192 · Cited by 244
Wu, B., Moulton, H. M., Iversen, P. L., Jiang, J., Li, J., Li, J., Spurney, C. F., Sali, A., Guerron, A. D., Nagaraju, K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805676105 · Cited by 236
“Most DMD mutations occur within the rod domain, which spans more than half the length of the protein, but seems to have limited functional importance (4, 5).”
BackgroundYin, H., Moulton, H. M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P., & Wood, M. J. A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn293 · Cited by 224
“Such partially functional protein retains the critical amino terminal, cysteine rich and C-terminal domains but usually lacks elements of the central rod domains which are of less functional significance (2).”
BackgroundEfficient in vivo gene expression by trans-splicing adeno-associated viral vectors
Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J. F., Chamberlain, J. S., & Duan, D. (2005) · Nature Biotechnology · doi:10.1038/nbt1153 · Cited by 224
“The ΔH2 minigene was developed from a truncated, but highly functional, patient-derived gene (Δexon17-48”
BackgroundProgress toward Gene Therapy for Duchenne Muscular Dystrophy
Chamberlain, J. R., & Chamberlain, J. S. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.019 · Cited by 224
“One was the identification of rare patients with large deletions within the gene, in one case encompassing almost half the gene, that were associated with extremely mild cases of BMD.6 A second came from isolation of the muscle cDNA, which was 14 kb but had an 11.2-kb open reading frame.”
BackgroundInfluentialAdvances in Duchenne muscular dystrophy gene therapy
van Deutekom, J. C. T., & van Ommen, G.-J. B. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1180 · Cited by 221
“A large range of deletions in dystrophin cause only mild phenotypes in BMD patients (for a notable example, see Ref”
A new model for the interaction of dystrophin with F-actin.
Rybakova, I. N., Amann, K. J., & Ervasti, J. M. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.3.661 · Cited by 220
“, 1996) and rod domains (England et al., 1990) also appear to be essential for normal dystrophin function.”
BackgroundWang, Z., Kuhr, C. S., Allen, J. M., Blankinship, M., Gregorevic, P., Chamberlain, J. S., Tapscott, S. J., & Storb, R. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300161 · Cited by 218
Identification of a chromosome 6-encoded dystrophin-related protein.
Khurana, T. S., Hoffman, E. P., & Kunkel, L. M. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44816-2 · Cited by 206
Fiber regeneration is not persistent in dystrophic (MDX) mouse skeletal muscle
DiMario, J. X., Uzman, A., & Strohman, R. C. (1991) · Developmental Biology · doi:10.1016/0012-1606(91)90340-9 · Cited by 206
Gene Therapy for Duchenne Muscular Dystrophy
Elangkovan, N., & Dickson, G. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210678 · Cited by 196
“One striking case study has revealed a 61-year old BMD patient who was still ambulant even though 46% of the coding information was lost in the deletion in his DMD gene [25].”
BackgroundInfluentialBushby, K. M. D., & Gardner-Medwin, D. (1993) · Journal of Neurology · doi:10.1007/bf00858725 · Cited by 203
Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense
Aartsma-Rus, A., Janson, A. A. M., Kaman, W. E., Bremmer-Bout, M., van Ommen, G.-J. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2004) · The American Journal of Human Genetics · doi:10.1086/381039 · Cited by 200
“Furthermore , it offers the therapeutic potential of generating relatively large in-frame deletions known to be associated with mild BMD phenotypes (England et al. 1990; Winnard et al. 1993; Mirabella et al. 1998).”
BackgroundVincent, N., Ragot, T., Gilgenkrantz, H., Couton, D., Chafey, P., Grégoire, A., Briand, P., Kaplan, J.-C., Kahn, A., & Perricaudet, M. (1993) · Nature Genetics · doi:10.1038/ng1093-130 · Cited by 201
Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMD
Pichavant, C., Aartsma-Rus, A., Clemens, P. R., Davies, K. E., Dickson, G., Takeda, S., Wilton, S. D., Wolff, J. A., Wooddell, C. I., Xiao, X., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.59 · Cited by 193
Self-citationPoint mutations in the dystrophin gene.
Roberts, R. G., Bobrow, M., & Bentley, D. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2331 · Cited by 192
Brain dystrophin, neurogenetics and mental retardation
Mehler, M. F. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00090-9 · Cited by 191
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
Bez Batti Angulski, A., Hosny, N., Cohen, H., Martin, A. A., Hahn, D., Bauer, J., & Metzger, J. M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1183101 · Cited by 173
“In BMD, mutations cause the loss of some exons but do not abolish dystrophin expression, as in the case of DMD (England et al., 1990).”
BackgroundHuman Adenovirus Vectors for Gene Transfer into Mammalian Cells
Hitt, M. M., Addison, C. L., & Graham, F. L. (1997) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60140-4 · Cited by 186
Forced expression of dystrophin deletion constructs reveals structure-function correlations.
Rafael, J. A., Cox, G. A., Corrado, K., Jung, D., Campbell, K. P., & Chamberlain, J. S. (1996) · The Journal of cell biology · doi:10.1083/jcb.134.1.93 · Cited by 184
Fletcher, S., Honeyman, K., Fall, A. M., Harding, P. L., Johnsen, R. D., & Wilton, S. D. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.838 · Cited by 182
“In some cases, BMD may only be diagnosed late in life, clearly indicating that segments of the protein, particularly in the rod domain, are not required for near-normal dystrophin function [4,5].”
BackgroundTherapeutic Strategies for Duchenne Muscular Dystrophy: An Update
Sun, C., Shen, L., Zhang, Z., & Xie, X. (2020) · Genes · doi:10.3390/genes11080837 · Cited by 173
“While microdystrophin cannot fully restore the function of WT dystrophin without C-terminal domain, the 6 kb minidystrophin gene contains all functional domains and displays better bioactivity compared to microdystrophin [84].”
BackgroundLiu, M., Yue, Y., Harper, S. Q., Grange, R. W., Chamberlain, J. S., & Duan, D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.013 · Cited by 178
“In an extreme case, a patient lacking 43% of dystrophin coding sequences has remained ambulant past age 61 [9].”
BackgroundCox, G. A., Sunada, Y., Campbell, K. P., & Chamberlain, J. S. (1994) · Nature Genetics · doi:10.1038/ng1294-333 · Cited by 171
Genetic therapies for RNA mis-splicing diseases
Hammond, S. M., & Wood, M. J. A. (2011) · Trends in Genetics · doi:10.1016/j.tig.2011.02.004 · Cited by 165
Chelly, J., Gilgenkrantz, H., Lambert, M., Hamard, G., Chafey, P., Récan, D., Katz, P., Chapelle, A. D. L., Koenig, M., Ginjaar, I. B., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90419-f · Cited by 162
Wu, B., Li, Y., Morcos, P. A., Doran, T. J., Lu, P., & Lu, Q. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.38 · Cited by 158
Morpholino Oligomer–Mediated Exon Skipping Averts the Onset of Dystrophic Pathology in the mdx Mouse
Fletcher, S., Honeyman, K., Fall, A. M., Harding, P. L., Johnsen, R. D., Steinhaus, J. P., Moulton, H. M., Iversen, P. L., & Wilton, S. D. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300245 · Cited by 158
Pharmacological advances for treatment in Duchenne muscular dystrophy
Guiraud, S., & Davies, K. E. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.002 · Cited by 159
Self-citationWells, D. J., Wells, K. E., Asante, E. A., Turner, G., Sunada, Y., Campbell, K. P., Walsh, F. S., & Dickson, G. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.8.1245 · Cited by 155
Antisense Oligonucleotide-induced Exon Skipping Across the Human Dystrophin Gene Transcript
Wilton, S. D., Fall, A., Harding, P. L., McClorey, G., Coleman, C., & Fletcher, S. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300095 · Cited by 153
The Binding Protein for Globular Heads of Complement C1q, gC1qR
Lim, B. L., Reid, K. B. M., Ghebrehiwet, B., Peerschke, E. I. B., LEIGH, L. E. A., & Preissner, K. T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.43.26739 · Cited by 153
Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy
Nicholson, L. V. B., Johnson, M. A., Gardner‐Medwin, D., Bhattacharya, S. S., & Harris, J. B. (1990) · Acta Neuropathologica · doi:10.1007/bf00294640 · Cited by 152
“Genetic analysis has yet to be completed on the majority of the patients in this study so we are unable to estimate the true number of biopsies for which a "false negative" result has been reported, but detailed investigations on one such patients have been completed [16].”
BackgroundSelf-citationGillis, J. (1999) · Journal of Muscle Research and Cell Motility · doi:10.1023/a:1005545325254 · Cited by 169
“Mutations resulting in the absence of dystrophin are responsible for the very severe Duchenne phenotypes, while in milder diseases, called Becker dystrophy, dystrophin is expressed in low levels or in some truncated forms (Monaco et al., 1988; England et al., 1990).”
BackgroundExpression of the N‐terminal domain of dystrophin in E. coli and demonstration of binding to F‐actin
Way, M., Pope, B. J., Cross, R. A., Kendrick‐Jones, J., & Weeds, A. G. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80249-g · Cited by 149
Satellite cell depletion in degenerative skeletal muscle
Jejurikar, S. S., & Kuzon, W. M. (2003) · APOPTOSIS · doi:10.1023/a:1026127307457 · Cited by 169
Dystrophin Expression in Muscles of mdx Mice After Adenovirus-Mediated In Vivo Gene Transfer
Acsádi, G., Lochmüller, H., Jáni, Á., Huard, J., Massie, B., Prescott, S. M., Simoneau, M., Petrof, B. J., & Karpati, G. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.2-129 · Cited by 149
“The transfer plasmids pAdCMV-dys and pAdRSV-dys were generated by inserting the 6.3-kb Becker-type dysti-ophin cDNA (England et al, 1990; Acsadi et al, 1992) into pADBMl (Lamarche et al, 1990), under the control of either the C MV promoter/enhancer or RSV long terminal repeat (LTR) and flanked by…”
InfluentialDMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations
Juan‐Mateu, J., González‐Quereda, L., Rodríguez, M. J., Baena, M., Verdura, E., Nascimento, A., Ortez, C., Baiget, M., & Gallano, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135189 · Cited by 150
“Initially, it was thought that the spectrin-like repeats had a very low importance in the overall function of dystrophin, since in-frame deletions removing large portions of the rod domain were observed in mild phenotypes [53].”
BackgroundThe genetic toxicology of acridines
Ferguson, L. R., & Denny, W. A. (1991) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(91)90006-h · Cited by 145
Pharmaceutical therapies to recode nonsense mutations in inherited diseases
Lee, H.-L. R., & Dougherty, J. P. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.007 · Cited by 145
Spectrin, α-Actinin, and Dystrophin
Broderick, M., & Winder, S. J. (2005) · Advances in protein chemistry · doi:10.1016/s0065-3233(05)70007-3 · Cited by 167
“Interestingly , the cysteine-rich domain is never deleted in BMD patients, suggesting that this domain is critical for dystrophin function as the BMD phenotypes are less severe (Rafael et al., 1996).”
BackgroundInfluentialGene therapy of muscular dystrophy
Chamberlain, J. S. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2355 · Cited by 162
“The idea that truncated dystrophins could be functional came from observations that some mildly affected BMD patients have deletion mutations that remove large portions of the gene (20,21).”
Therapeutics for Duchenne muscular dystrophy: current approaches and future directions
Bogdanovich, S., Perkins, K. J., Krag, T. O. B., & Khurana, T. S. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0484-1 · Cited by 154
“This deletion [28] has been used as a basis for a”
BackgroundMethodCurrent Progress in Therapeutic Gene Editing for Monogenic Diseases
Prakash, V., Moore, M., & Yáñez‐Muñoz, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.5 · Cited by 150
Yuasa, K., Sakamoto, M., Miyagoe‐Suzuki, Y., Tanouchi, A., Yamamoto, H., Li, J., Chamberlain, J. S., Xiao, X., & Takeda, S. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301829 · Cited by 138
Yin, H., Moulton, H. M., Betts, C., Seow, Y., Boutilier, J. K., Iverson, P. L., & Wood, M. J. A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp395 · Cited by 137
Yin, H., Saleh, A. F. A., Betts, C., Camelliti, P., Seow, Y., Ashraf, S., Arzumanov, A. A., Hammond, S. M., Merritt, T. M., Gait, M. J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.79 · Cited by 135
“Antisense oligonucleotide (AO)-mediated exon skipping can restore the open reading frame of mutant DMD pre-mRNA transcripts [3-15] and produce truncated but partially functional dystrophin protein [16-17].”
Microdystrophin Ameliorates Muscular Dystrophy in the Canine Model of Duchenne Muscular Dystrophy
Shin, J., Pan, X., Hakim, C. H., Yang, H. T., Yue, Y., Zhang, K., Terjung, R. L., & Duan, D. (2013) · Molecular Therapy · doi:10.1038/mt.2012.283 · Cited by 146
The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy
Bushby, K. M. D., Gardner‐Medwin, D., Nicholson, L. V. B., Johnson, M. A., Haggerty, I. D., Cleghorn, N., Harris, J. B., & Bhattacharyal, S. S. (1993) · Journal of Neurology · doi:10.1007/bf00858726 · Cited by 132
Self-citationTherapeutic approaches for Duchenne muscular dystrophy
Roberts, T. C., Wood, M. J. A., & Davies, K. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00775-6 · Cited by 147
“…events have been reported, related to muscle weakness and myocarditis, leading to a protocol amendment to exclude patients with mutations that affect DMD exons 9–13, or deletions that affect both exons 29 and 30, and to include a 7-day hospitalization period after treatment administration 117,118 .”
BackgroundSelf-citationGreenberg, D., Sunada, Y., Campbell, K. P., Yaffe, D., & Nudel, U. (1994) · Nature Genetics · doi:10.1038/ng1294-340 · Cited by 129
Wu, B., Lu, P., Benrashid, E., Malik, S. C., Ashar, J., Doran, T. J., & Lu, Q. L. (2009) · Gene Therapy · doi:10.1038/gt.2009.120 · Cited by 128
Dystrophin levels and clinical severity in Becker muscular dystrophy patients
van den Bergen, J. C., Wokke, B. H. A., Janson, A. A., van Duinen, S. G., Hulsker, M., Ginjaar, H. B., van Deutekom, J. C., Aartsma-Rus, A. M., Kan, H. E., & Verschuuren, J. J. G. M. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306350 · Cited by 126
Beekman, C., Janson, A. A., Baghat, A., van Deutekom, J. C., & Datson, N. A. (2018) · PLOS ONE · doi:10.1371/journal.pone.0195850 · Cited by 119
Deconinck, N., Ragot, T., Maréchal, G., Perricaudet, M., & Gillis, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3570 · Cited by 147
Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene
Sakamoto, M., Yuasa, K., Yoshimura, M., Yokota, T., Ikemoto, T., Suzuki, M., Dickson, G., Miyagoe‐Suzuki, Y., & Takeda, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00362-5 · Cited by 141
“Surprisingly, it has been shown that a large in-frame deletion in the central rod domain results in Becker muscular dystrophy, an allelic, milder form of DMD [12].”
BackgroundDevelopment of Novel Micro-dystrophins with Enhanced Functionality
Ramos, J. N., Hollinger, K., Bengtsson, N. E., Allen, J. M., Hauschka, S. D., & Chamberlain, J. S. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.002 · Cited by 126
Bremmer-Bout, M., Aartsma-Rus, A. M., de Meijer, E. J., Kaman, W. E., Janson, A. A. M., Vossen, R. H. A. M., van Ommen, G. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.031 · Cited by 120
Protein Trans -Splicing as a Means for Viral Vector-Mediated In Vivo Gene Therapy
Xiao, X., Li, J., Sun, W., Wang, B., & Liu, X. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.009 · Cited by 124
“This cDNA was isolated from a Becker muscular dystrophy patient more than 60 years of age with mild symptoms (England et al ., 1990).”
InfluentialGene therapy for muscular dystrophy: Lessons learned and path forward
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Malik, V., Kaspar, B. K., Walker, C. M., & Clark, K. R. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.04.078 · Cited by 124
“Two diseases with selective quadriceps muscle weakness are undergoing gene transfer including sporadic inclusion body myositis (sIBM) and Becker muscular dystrophy (BMD).”
BackgroundInfluentialDystrophin: More than just the sum of its parts
Rumeur, É. L., Winder, S. J., & Hubert, J. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.05.001 · Cited by 139
Metadata
- Authors
- England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E.
- Affiliations
- John Radcliffe Hospital (GB)
- Hospital for Sick Children (CA)
- Venue
- Nature
- Published
- 1990-01
- Volume
- 343
- Issue
- 6254
- Pages
- 180-182
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2058807250
- Cited by
- 623
- References
- 25
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 20 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 16 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 23 · 2014: 16 · 2013: 17 · 2012: 22
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- Becker muscular dystrophy, Duchenne muscular dystrophy, dystrophin gene deletion, dystrophin, X-linked inheritance, reading frame, gene therapy
- MeSH terms
- Chromosome Deletion, Exons, Female, Genes, Humans, Male, Middle Aged, Muscle Proteins, Muscles, Muscular Dystrophies, Nucleic Acid Hybridization, Pedigree, Protein Conformation, Reference Values, Blotting, Western, Restriction Mapping, Dystrophin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.